AbbVie touts more Rinvoq data in inflammatory spinal arthritis as it awaits key FDA decisions

[cafead]

via Despite a recent FDA label restriction, AbbVie is still churning out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor’s megablockbuster potential.

article source